Anlon Healthcare shares make a tepid debut. Should IPO investors wait or sell?

Anlon Healthcares shares debuted with a modest 1% premium amid volatile pharma markets, despite a strong 7.12x IPO subscription driven by retail investors. The specialized API manufacturer showed robust financial growth, with revenue up 81% in FY25 and expanding profit margins. While niche products and global approvals boost prospects, risks include limited operating history and regulatory challenges. Analysts consider the IPO fully priced.